Evaluation of the effectiveness and side effect profile in elderly patients with CRSwNP receiving dupilumab therapy
Laryngo-Rhino-Otologie · 01.05.2023 · 102 (S 02 S 02) · S335
DOI: 10.1055/s-0043-1767591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2023. Verfasst von Valeria Valova und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Biologica are a highly effective treatment options for severe chronic rhinosinusitis with nasal polyposis (CRSwNP). Little is known about CRSwNP in elderly patients. In the CRSwNP phase 3 study of dupilumab, the maximum age of the patients was 61 years. The aim of this prospective study was to investigate the effectiveness of rhinonasal parameters and the side effect profile in CRSwNP patients after 6 months of dupilumab therapy.
Methods
48 patients with severe uncontrolled CRSwNP and age ≥ 65 years (Ø 70 years; min 65 years; max 83 years; 22 female, 26 male) were included. The frequency of asthma, ASA intolerance, the frequency of previous NNH surgeries and ASS deactivation were evaluated. The nasal polyposis (NP) score and the sinonasal outcome test (SNOT)-22 were evaluated before and after 6 months of therapy. The frequency of self-application and side effects during dupilumab therapy were recorded.
Results
Asthma was present in 80% of the cases, ASS intolerance in 44%, NNH-OPs MW 3.2 and ASS deactivation had occurred in 14% of the patients. The NP score and the SNOT-22 were significantly reduced after 6 months of dupilumab therapy (NP score initially mean 4.43, after 6 months 1.47; p< 0.001; SNOT-22 initially mean 53,41, after 6 months 20.24, p< 0.001). Dupilumab injections were self-administered in 98% of cases. Joint pain (6%) and skin reddening (4%) were reported as side effects during dupilumab therapy.
Conclusions
Dupilumab therapy is a highly effective therapy with few side effects in elderly patients with severe CRSwNP. Publication History Article published online: 12 May 2023 Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Valova, V., Förster-Ruhrmann, U., & Olze, H. (2023). Evaluation of the effectiveness and side effect profile in elderly patients with CRSwNP receiving dupilumab therapy. Laryngo-Rhino-Otologie, 102(S 02 S 02), S335. https://doi.org/10.1055/s-0043-1767591
Vancouver
Valova V, Förster-Ruhrmann U, Olze H. Evaluation of the effectiveness and side effect profile in elderly patients with CRSwNP receiving dupilumab therapy. Laryngo-Rhino-Otologie. 2023;102(S 02 S 02):S335. doi:10.1055/s-0043-1767591
BibTeX
@article{Valova2023,
author = {Valova, Valeria and Förster-Ruhrmann, Ulrike and Olze, Heidi},
title = {Evaluation of the effectiveness and side effect profile in elderly patients with CRSwNP receiving dupilumab therapy},
journal = {Laryngo-Rhino-Otologie},
year = {2023},
volume = {102},
number = {S 02 S 02},
pages = {S335},
doi = {10.1055/s-0043-1767591}
}
EUVIMED